Assembly Biosciences Inc (ASMB)
14.72
-0.30
(-2.00%)
USD |
NASDAQ |
Nov 21, 16:00
14.79
+0.07
(+0.48%)
After-Hours: 20:00
Assembly Biosciences Revenue (Quarterly): 6.845M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 6.845M |
| June 30, 2024 | 8.533M |
| March 31, 2024 | 5.785M |
| December 31, 2023 | 7.163M |
| September 30, 2023 | |
| June 30, 2023 | |
| March 31, 2023 | |
| December 31, 2022 | |
| September 30, 2022 | |
| June 30, 2022 | |
| March 31, 2022 | |
| December 31, 2021 | |
| September 30, 2021 | 6.254M |
| June 30, 2021 | |
| March 31, 2021 | |
| December 31, 2020 | 1.037M |
| Date | Value |
|---|---|
| September 30, 2020 | 34.61M |
| June 30, 2020 | 39.38M |
| March 31, 2020 | 4.081M |
| December 31, 2019 | 4.766M |
| September 30, 2019 | 4.231M |
| June 30, 2019 | 3.08M |
| March 31, 2019 | 3.885M |
| December 31, 2018 | 3.735M |
| September 30, 2018 | 4.286M |
| June 30, 2018 | 3.218M |
| March 31, 2018 | 3.565M |
| December 31, 2017 | 3.316M |
| September 30, 2017 | 2.660M |
| June 30, 2017 | 2.359M |
| March 31, 2017 | 0.6844M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
1.037M
Minimum
Dec 2020
39.38M
Maximum
Jun 2020
11.85M
Average
6.550M
Median
Revenue (Quarterly) Benchmarks
| ADMA Biologics Inc | 119.84M |
| Sensus Healthcare Inc | 8.839M |
| Protagonist Therapeutics Inc | 4.675M |
| Precision BioSciences Inc | 0.576M |
| Entrada Therapeutics Inc | 19.57M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -9.613M |
| Total Expenses (Quarterly) | 17.80M |
| EPS Diluted (Quarterly) | -1.51 |
| Enterprise Value | -1.389M |
| Profit Margin (Quarterly) | -140.4% |
| Earnings Yield | -47.01% |
| Normalized Earnings Yield | -47.01 |